American Journal of Kidney Diseases
Volume 56, Issue 5 , Pages 852-860 , November 2010

Predictors of Incident Albuminuria in the Framingham Offspring Cohort

  • Conall M. O'Seaghdha, MD

      Affiliations

    • Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
    • National Heart, Lung and Blood Institute's Framingham Heart Study and the Center for Population Studies, Framingham, MA
    • ,
  • Shih-Jen Hwang, PhD

      Affiliations

    • National Heart, Lung and Blood Institute's Framingham Heart Study and the Center for Population Studies, Framingham, MA
    • ,
  • Ashish Upadhyay, MD

      Affiliations

    • Division of Nephrology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA
    • ,
  • James B. Meigs, MD, MPH

      Affiliations

    • General Medicine Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    • ,
  • Caroline S. Fox, MD, MPH

      Affiliations

    • National Heart, Lung and Blood Institute's Framingham Heart Study and the Center for Population Studies, Framingham, MA
    • Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
    • Corresponding Author InformationAddress correspondence to Caroline S. Fox, MD, MPH, National Heart, Lung and Blood Institute's Framingham Heart Study, 73 Mt Wayte Ave, Ste 2, Framingham, MA 01702

Received 17 December 2009 ,Accepted 7 April 2010.

References 

  1. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777–1782
  2. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005;94:S14–S18
  3. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249(6):519–526
  4. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? (The Nord-Trondelag Health Study (HUNT), Norway). Circulation. 2003;108(22):2783–2789
  5. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–2063
  6. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17(8):2100–2105
  7. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol. 2006;17(2):331–335
  8. Forman JP, Fisher ND, Schopick EL, Curhan GC. Higher levels of albuminuria within the normal range predict incident hypertension. J Am Soc Nephrol. 2008;19(10):1983–1988
  9. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) Study. J Am Coll Cardiol. 2008;51(18):1775–1783
  10. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18–S21
  11. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care. 2005;28(10):2525–2530
  12. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families (The Framingham Offspring Study). Am J Epidemiol. 1979;110(3):281–290
  13. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279–281
  14. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617–622
  15. Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care. 1987;10(4):414–418
  16. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13(4):1034–1039
  17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266
  18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130(6):461–470
  19. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–850
  20. Boddana P, Caskey F, Casula A, Ansell D. UK Renal Registry 11th Annual Report (December 2008): chapter 14 UK Renal Registry and international comparisons. Nephron Clin Pract. 2009;111(suppl 1):c269–c276
  21. Franciosi M, Pellegrini F, Sacco M, et al. Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol. 2007;2(5):984–991
  22. Meigs JB, D'Agostino RB, Nathan DM, Rifai N, Wilson PW. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care. 2002;25(6):977–983
  23. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
  24. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
  25. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT (Multiple Risk Factor Intervention Trial). JAMA. 1997;278(23):2069–2074
  26. Thomas MC, Macisaac RJ, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment Co-existing With NIDDM [NEFRON] 11). Diabetes Care. 2009;32(8):1497–1502
  27. Bruno G, Merletti F, Biggeri A, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2003;26(7):2150–2155
  28. Tolonen N, Forsblom C, Thorn L, et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia. 2009;52(12):2522–2530
  29. Marcovecchio ML, Dalton RN, Prevost AT, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009;32(4):658–663
  30. Microalbuminuria Collaborative Study Group, United Kingdom. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ. 1993;306(6887):1235–1239
  31. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25(5):859–864
  32. Ishizaka N, Ishizaka Y, Toda E, et al. Association between cigarette smoking and chronic kidney disease in Japanese men. Hypertens Res. 2008;31(3):485–492
  33. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med. 2000;133(8):585–591
  34. Cirillo M, Senigalliesi L, Laurenzi M, et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. Arch Intern Med. 1998;158(17):1933–1939
  35. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population?. J Am Soc Nephrol. 2007;18(2):637–645
  36. Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. Diabet Med. 2007;24(10):1136–1142
  37. The Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med. 1999;16(11):918–925
  38. Solbu MD, Kronborg J, Eriksen BO, Jenssen TG, Toft I. Cardiovascular risk-factors predict progression of urinary albumin-excretion in a general, non-diabetic population: a gender-specific follow-up study. Atherosclerosis. 2008;201(2):398–406
  39. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997;94(25):13915–13920
  40. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992;89(24):12043–12047
  41. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315–1321
  42. Janzon L, Berntorp K, Hanson M, Lindell SE, Trell E. Glucose tolerance and smoking: a population study of oral and intravenous glucose tolerance tests in middle-aged men. Diabetologia. 1983;25(2):86–88
  43. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet. 1992;339(8802):1128–1130
  44. Forsblom CM, Eriksson JG, Ekstrand AV, Teppo AM, Taskinen MR, Groop LC. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia. 1995;38(3):363–369
  45. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74(1):22–36
  46. Forman JP, Brenner BM. ‘Hypertension’ and ‘microalbuminuria’: the bell tolls for thee. Kidney Int. 2006;69(1):22–28
  47. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int. 2002;61(1):209–218
  48. Xu J, Lee ET, Devereux RB, et al. A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: the Strong Heart Study. Am J Kidney Dis. 2008;51(3):415–424
  49. Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension. 2005;45(6):1125–1130
  50. Janssen WM, Hillege H, Pinto-Sietsma SJ, Bak AA, De Zeeuw D, de Jong PE. Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clin Chem Lab Med. 2000;38(11):1107–1110
  51. Verhave JC, Hillege HL, Burgerhof JG, Navis G, de Zeeuw D, de Jong PE. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol. 2003;14(5):1330–1335
  52. Lazzara MJ, Deen WM. Model of albumin reabsorption in the proximal tubule. Am J Physiol Renal Physiol. 2007;292(1):F430–F439
  53. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809–2816
  54. Cohen DL, Close CF, Viberti GC. The variability of overnight urinary albumin excretion in insulin-dependent diabetic and normal subjects. Diabet Med. 1987;4(5):437–440
  55. Brinkman JW, de Zeeuw D, Lambers Heerspink HJ, et al. Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry. Clin Chem. 2007;53(8):1520–1526
  56. Whaley-Connell A, Pavey BS, Afroze A, Bakris GL. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006;1(3):209–214

 This is a US Government Work. There are no restrictions on its use.

 Originally published online as doi:10.1053/j.ajkd.2010.04.013 on July 5, 2010.

 Because a quorum could not be reached after those editors with potential conflicts recused themselves from consideration of this manuscript, the peer-review and decision-making processes were handled entirely by an Associate Editor (Tazeen H. Jafar, MD, MPH, Aga Khan University) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(10)00845-0

doi: 10.1053/j.ajkd.2010.04.013

American Journal of Kidney Diseases
Volume 56, Issue 5 , Pages 852-860 , November 2010

Article Tools